Drug Trial Radar · NCT07285655
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
344
Planned (sponsor's estimate)
Start
Apr 23, 2026
Primary completion
Jul 2029
Study completion Dec 2031
Sponsor
- Lead sponsor
- Liquidia Technologies, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to find out if L606 is safe and if it helps people with high blood pressure in the lungs (pulmonary hypertension) caused by interstitial lung disease (PH-ILD, WHO Group 3). One of the main ways the study will check this is by seeing if people can walk further in six minutes (called the "six-minute walk test"). Another important (secondary) goal is to see how long it takes for PH-ILD to get worse while people are taking L606. One way the study will measure this is by looking at the distance people walk at different times in the study on different doses of L606. Throughout the study, doctors will also closely monitor for any side effects people have to make sure L606 is safe. People who decide to join this study will be randomly (like tossing a coin) placed into one of two groups: one group will get L606 and the other group will get a placebo, which will look like L606 but will not contain any active medicine. At the end of the initial blinded portion of the study, study participants may have the opportunity to enroll in an open-label extension portion of the study where all participants will receive L606.
Conditions
- Pulmonary Hypertension Due to Lung Disease (Disorder)
Interventions
L606Drug
L606 is a liposomal version of treprostinil intended for delivery via oral inhalation using a study issued nebulizer.
PlaceboDrug
Placebo will match L606 but contain no treprostinil.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in 6-minute walk distance (6MWD) as evaluated by the 6-minute walk test (6MWT)Time frame: 16 weeks
Locations
44 sites in 12 countries. Site status is shown where the registry gives one.
Dignity Health - St. Joseph's Hospital and Medical Center
Phoenix, Arizona · Recruiting
Arizona Pulmonary Specialists, Ltd.
Scottsdale, Arizona · Recruiting
David Geffen School of Medicine at UCLA
Los Angeles, California · Recruiting
University of California, San Francisco
San Francisco, California · Recruiting
University of Colorado Hospital
Aurora, Colorado · Recruiting
National Jewish Hospital
Denver, Colorado · Recruiting
Tampa General Hospital
Tampa, Florida · Recruiting
Northwestern University
Chicago, Illinois · Recruiting
St. Vincent Cardiovascular Research Institute
Indianapolis, Indiana · Recruiting
NYU Langone Health
New York, New York · Recruiting
University of Rochester Medical Center
Rochester, New York · Recruiting
Summit Health
Bend, Oregon · Recruiting
Medical University of South Carolina- Nexus Research Clinic
Charleston, South Carolina · Recruiting
Royal Hobart Hospital
Hobart, Tasmania, Australia · Recruiting
Ordensklinikum Linz GmbH
Linz, Austria · Recruiting
Hopital Erasme
Anderlecht, Belgium · Recruiting
Universitair Ziekenhuis Gent
Ghent, Belgium · Recruiting
UZ Leuven
Leuven, Belgium · Recruiting
Peter Lougheed Center
Calgary, Canada · Recruiting
Hospices Civils De Lyon
Bron, France · Recruiting
Assistance Publique Hopitaux De Paris
Le Kremlin-Bicêtre, France · Recruiting
Universitaetsklinikum Koeln AöR
Cologne, Germany · Recruiting
Ruhrlandklinik Westdeutsches Lungenzentrum Am Universitaetsklinikum Essen GmbH
Essen, Germany · Recruiting
Universitätsklinikum Giessen und Marburg - Standort Giessen
Giessen, Germany · Recruiting
Universitaetsmedizin Greifswald KöR
Greifswald, Germany · Recruiting
University Medical Center Hamburg-Eppendorf
Hamburg, Germany · Recruiting
Medizinische Hochschule Hannover
Hanover, Germany · Recruiting
Krankenhaus Neuwittelsbach
Munich, Germany · Recruiting
LMU Klinikum Muenchen AöR
Munich, Germany · Recruiting
IRCCS Ospedale Policlinico San Martino
Genoa, Italy · Recruiting
Fondazione IRCCS Policlinico San Matteo
Pavia, Italy · Recruiting
Azienda Ospedaliero-Universitaria Policlinico Umberto I
Rome, Italy · Recruiting
Pauls Stradinš Clinical University Hospital
Riga, Latvia · Recruiting
Unidade Local De Saude De Almada-Seixal E.P.E.
Almada, Portugal · Recruiting
Unidade Local De Saude De Coimbra E.P.E.
Coimbra, Portugal · Recruiting
Unidade Local De Saude De Santo Antonio E.P.E.
Porto, Portugal · Recruiting
Hospital Del Mar
Barcelona, Spain · Recruiting
Hospital Clinic De Barcelona
Barcelona, Spain · Recruiting
Hospital Universitario Marques De Valdecilla
Santander, Spain · Recruiting
Royal United Hospitals Bath NHS Foundation Trust
Bath, United Kingdom · Recruiting
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.